$CERE News
Last published 1y ago
- 1y agoANROCERERAPPAlto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of DirectorsBusiness WireAlto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond
- 1y agoCERESHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cerevel Therapeutics Holdings, Inc....
- 1y agoCEREEntwistle & Cappucci LLP is Investigating Potential Federal Securities Law Violations in Connection with Cerevel Therapeutics Holdings, Inc. (CERE)Business WireEntwistle & Cappucci LLP ("Entwistle & Cappucci") is investigating potential federal securities law violations on behalf of its clients and other former holders of Cerevel Therapeutics Holdings, Inc. ("Cerevel"
- 2y agoOGENABTBIIBPFE+2As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032PR NewswireA concussion is a mild traumatic brain injury temporarily disrupting the brain's normal function. Generally, concussions are induced by a blow or...
- 2y agoABBVCEREAbbVie Completes Acquisition of Cerevel TherapeuticsPR NewswireAbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE). With the completion of the...
- 2y agoCERECerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's DiseaseGlobeNewswireTavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total "on" time without troublesome dyskinesia compared with placebo over 27 weeks
- 2y agoMDCWAVDNSCEREKuehn Law Encourages MDC, WAVD, NS and CERE Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoCEREHAIMGNWAVDKuehn Law Encourages CERE, HA, IMGN, and WAVD Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoCERECERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding AbbVie's Proposed Acquisition of Cerevel TherapeuticsPR NewswireJulie & Holleman LLP, a nationally recognized shareholder rights law firm, is investigating the proposed $45 per share sale of Cerevel Therapeutics...
- 2y agoCEREABBVAbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billionCNBCThe deal is AbbVie's latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic competition.
- 2y agoABBVCEREAbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience PipelinePR NewswireAbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel...
- 2y agoCERECerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson's DiseaseGlobeNewswireEvent will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson's disease Live webcast scheduled for Monday, December 11 from 10:00 to 11:30 a.m. ET CAMBRIDGE, Mass., Nov.
- 3y agoCERECerevel Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that members of the
- 3y agoCERECerevel Therapeutics Holdings, Inc. (CERE) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoCERECerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdatesGlobeNewswireRaised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track Tavapadon
- 3y agoCERECerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023GlobeNewswireCAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third
- 3y agoCERECerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the
- 3y agoCERECerevel Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that
- 3y agoCERECerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the
- 3y agoCERECerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdatesGlobeNewswireThree new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated Cash, cash
- 3y agoCERECerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023GlobeNewswireCAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second
- 3y agoCERECerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations OfficerGlobeNewswireMr. Burgess will be responsible for leading Cerevel's business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel
- 3y agoCERECerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial OfficerGlobeNewswireSusan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May
- 3y agoCERECerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial ResultsGlobeNewswireRon Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023; Dr. Coles will continue as chairperson of the board Mr. Renaud brings more than 25 years of biotechnology leadership to Cerevel, including two
- 3y agoCERECerevel Therapeutics to Present at the BofA Securities 2023 Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and
- 3y agoCERECerevel Therapeutics to Report First Quarter 2023 Financial Results and Business Updates on Wednesday, May 3, 2023GlobeNewswireCAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first
- 3y agoCERECerevel Therapeutics to Present at the Stifel 2023 CNS DaysGlobeNewswireCAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson
- 3y agoCERECerevel Therapeutics to Present at the 43rd Annual Cowen Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson
- 3y agoCERECerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business UpdatesGlobeNewswireEmraclidine Phase 1 healthy elderly volunteer trial enrollment underway to support development in Alzheimer's disease psychosis Emraclidine Phase 2 schizophrenia data readout remains on track for 1H 2024 Clinical trial
- 3y agoCERECerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023GlobeNewswireCAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth
- 3y agoCERECerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline UpdateGlobeNewswireInitiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer's disease psychosis in Q4 2022; second potential indication as a once-daily treatment Phase 2 proof-of-concept darigabat panic
- 3y agoCERECerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and
- 3y agoCERECerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring TrialGlobeNewswireData provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with schizophrenia Emraclidine demonstrated a mean change from baseline in 24-hour
- 3y agoCERECerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with SchizophreniaGlobeNewswireEmraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration Data show clinically meaningful and statistically significant improvement with emraclidine in PANSS
- 4y agoCERECerevel Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the
- 4y agoCERECerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business UpdatesGlobeNewswireCompleted $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline Initiated EMPOWER-3, a 52-week open-label extension trial of emraclidine in people with
- 4y agoCERECerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022GlobeNewswireCAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third
- 4y agoCERECerevel Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the
- 4y agoCERECerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. ("Cerevel", "we", "us" or "our") (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pri
- 4y agoCERECerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior NotesGlobeNewswireCAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. ("Cerevel", "we", "us" or "our") (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pri
- 4y agoCERECerevel Therapeutics Announces Proposed Private Offering of Convertible Senior NotesGlobeNewswireCAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. ("Cerevel", "we", "us" or "our") (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it
- 4y agoCERECerevel Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. ("Cerevel", "we", "us" or "our") (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it
- 4y agoCERECerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business UpdatesGlobeNewswireInitiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024 Phase 1 trial of emraclidine to be initiated by year-end to support future development in Alzheimer's disease psychosis Panic diso
- 4y agoCERECerevel Therapeutics to Report Second Quarter 2022 Financial Results and Pipeline Update on Monday, August 1, 2022GlobeNewswireCAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2022 financial results
- 4y agoCERECerevel Therapeutics Announces Updates to its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has appointed Suneet Varma to serve as a mem
- 4y agoCERECerevel Therapeutics to Present at the Jefferies Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer Tony Coles, M.
- 4y agoCERECerevel Therapeutics Reports First Quarter 2022 Financial Results and Business UpdatesGlobeNewswireOn track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2 proof-of-concept trial in focal epilepsy now expected mid-year 2023, revised from 2H 2022 $550.9M in
- 4y agoCERECerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022GlobeNewswireCAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2022 financial results
- 4y agoCERECerevel Therapeutics to Present at the Stifel 4th Annual CNS Day EventGlobeNewswireCAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer, Tony Coles,
- 4y agoCERECerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswireAnnounced positive results from Phase 1 healthy volunteer trial of darigabat in acute anxiety On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Multiple late-stage clinical readout